Literature DB >> 1543183

The case against screening urinalyses for asymptomatic bacteriuria in children.

K J Kemper1, E D Avner.   

Abstract

Screening children for asymptomatic bacteriuria to prevent pyelonephritis and renal scarring is widely recommended, but its cost-effectiveness has not been established. We reviewed published studies to determine the costs and benefits of screening toilet-trained, asymptomatic children for bacteriuria. Given the sensitivity and specificity of current screening methods (approximately 80% each) and the prevalence of bacteriuria in asymptomatic children (approximately 1% in girls and 0.03% in boys), screening 100,000 children would result in 19,897 (20%) false-positive tests; initial screening and two urine cultures to confirm the diagnosis of asymptomatic bacteriuria would miss 28% of 515 children with true bacteriuria, and cost nearly $2.9 million. There is no evidence that detection and treatment of children with asymptomatic bacteriuria prevents subsequent pyelonephritis or renal scarring. Screening for bacteriuria in asymptomatic children is costly, fails to prevent pyelonephritis or renal scarring, and should be discontinued as a part of routine well-child care.

Entities:  

Mesh:

Year:  1992        PMID: 1543183     DOI: 10.1001/archpedi.1992.02160150083027

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  6 in total

Review 1.  Treatment of urinary tract infection. Clinical and economic considerations.

Authors:  R J Plumridge; C L Golledge
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 2.  Screening Urinalysis in Detection of Chronic Kidney Disease in Children.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Indian J Pediatr       Date:  2018-05-23       Impact factor: 1.967

3.  Aspects of clinical trials of drug efficacy in children with uncomplicated infections.

Authors:  U Jodal
Journal:  Infection       Date:  1994       Impact factor: 3.553

4.  Urinary tract infection pattern in adult women followed from childhood.

Authors:  Carin Gebäck; Sverker Hansson; Jeanette Martinell; Torsten Sandberg; Ulf Jodal
Journal:  Pediatr Nephrol       Date:  2016-02-15       Impact factor: 3.714

Review 5.  Long-term, low-dose prophylaxis against urinary tract infections in young children.

Authors:  Per Brandström; Sverker Hansson
Journal:  Pediatr Nephrol       Date:  2014-06-07       Impact factor: 3.714

6.  Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children.

Authors:  Staffan Mårild; Ulf Jodal; Torsten Sandberg
Journal:  Pediatr Nephrol       Date:  2008-09-26       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.